Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term renal and systemic effects of dapagliflozin in non-diabetic stage IV chronic kidney disease
2021-000726-10Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dapagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Glomerular filtration rate. Started Jun 2021; status: completed.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2021-000726-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000726-10.